Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-05-08 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业关于控股子公司业绩承诺补偿涉及诉讼的进展公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding the progress of a litigation case involving the company's controlling subsidiary's performance compensation. It details court decisions, appeals, and legal proceedings but does not contain financial statements or performance data. The document is a legal proceedings update rather than a financial report or other filing type. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is 1838 characters, which is consistent with an announcement rather than a full report.
2023-05-08 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 30th meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, voting results, and references to the approval of the company's 2023 first quarter report and the proposal to convene the 2022 annual general meeting. The document is short (739 characters) and primarily serves to disclose board meeting decisions rather than the full report itself. It also references where the full quarterly report and AGM notice can be found, indicating this is a meeting resolution announcement rather than the report or the AGM materials themselves. Therefore, this fits best under Board/Management Information (MANG).
2023-04-28 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '金陵药业股份有限公司2023 年第一季度报告' which translates to 'Jinling Pharmaceutical Co., Ltd. 2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial indicators for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter ending March 31, 2023. It also mentions that the report is unaudited. The length of the document (12,287 characters) and the detailed financial content confirm it is a full interim/quarterly financial report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-28 Chinese
金陵药业关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and procedural details for the AGM. The document length is 4327 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-04-28 Chinese
金陵药业2023年度向特定对象发行A股股票募集说明书（申报稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（申报稿）" which translates to "Offering Prospectus (Filing Draft)" for a specific issuance of A shares by Jinling Pharmaceutical Company Limited. It details the issuance method, pricing, number of shares, use of proceeds, risk factors, and other information related to a capital raising event. The document is comprehensive and contains detailed information about the share issuance to specific investors, including regulatory approvals and investment risks. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an annual report, earnings release, or other report types. The document length (15,000 characters) and content confirm it is the actual prospectus, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is CAP with high confidence.
2023-04-28 Chinese
江苏泰和律师事务所关于金陵药业 2023年度向特定对象发行A股股票的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2023 private placement (向特定对象发行) of A shares by Jinling Pharmaceutical Co., Ltd. It extensively discusses the approval, authorization, legal compliance, issuance plan, pricing, lock-up periods, and use of proceeds related to the issuance of new shares. The document references regulatory frameworks such as the Company Law, Securities Law, and registration rules, and includes detailed legal and procedural analysis. This is not a general annual or interim financial report, nor is it an earnings release or a simple announcement. It is a legal opinion specifically related to a capital raising event through a private placement of shares. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the full legal opinion, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to the specificity and detailed nature of the legal opinion on the share issuance.
2023-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.